Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in leaving the study early: any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
2 findings from 1 review
Leaving the study early · patients with schizophrenia
Beta‐blockers showed no clear difference in global state: 1. Leaving the study early ‐ Short term compared with placebo (low certainty).
1 finding from 1 review
Pre‐eclampsia · women who are not yet pregnant and women in the early stages of pregnancy
Calcium supplementation showed no clear difference in pre‐eclampsia compared with placebo (maternal outcomes) commencing before or early (low certainty).
1 finding from 1 review
Pre‐eclampsia, or pregnancy loss, or stillbirth (or combination) at any gestational age · women who are not yet pregnant and women in the early stages of pregnancy
Calcium supplementation showed no clear difference in pre‐eclampsia, or pregnancy loss, or stillbirth (or combination) at… compared with placebo (maternal outcomes) commencing before or early (low certainty).
1 finding from 1 review
Severe maternal morbidity and mortality index · women who are not yet pregnant and women in the early stages of pregnancy
Calcium supplementation showed no clear difference in severe maternal morbidity and mortality index compared with placebo (maternal outcomes) commencing before or early (low certainty).
1 finding from 1 review
Pregnancy loss or stillbirth at any gestational age · women who are not yet pregnant and women in the early stages of pregnancy
Calcium supplementation showed no clear difference in pregnancy loss or stillbirth at any gestational age compared with placebo (maternal outcomes) commencing before or early (low certainty).
1 finding from 1 review
Caesarean section · women who are not yet pregnant and women in the early stages of pregnancy
Calcium supplementation showed no clear difference in caesarean section compared with placebo (maternal outcomes) commencing before or early (low certainty).
1 finding from 1 review
Low birthweight · women who are not yet pregnant and women in the early stages of pregnancy
Calcium showed no clear difference in birthweight < 2500 g compared with placebo (offspring outcomes) commencing before or early (low certainty).
1 finding from 1 review
Apgar score less than 7 at 5 minutes · women who are not yet pregnant and women in the early stages of pregnancy
It is very uncertain whether calcium changes apgar < 7 at 5 minutes compared with placebo (offspring outcomes) commencing before or early (very low certainty).
1 finding from 1 review
Perinatal death, or NICU admission for > 24 hours (or both) · women who are not yet pregnant and women in the early stages of pregnancy
Calcium showed no clear difference in perinatal death, or NICU admission for > 24 hours (or both) compared with placebo (offspring outcomes) commencing before or early (low certainty).
1 finding from 1 review
Pregnancy loss, stillbirth or neonatal death before discharge · women who are not yet pregnant and women in the early stages of pregnancy
Calcium showed no clear difference in pregnancy loss, stillbirth or NND before discharge compared with placebo (offspring outcomes) commencing before or early (low certainty).
1 finding from 1 review
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
Angiotensin‐converting enzyme inhibitors showed no clear difference in death (any cause) compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Kidney failure progression · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found